PMID: 9522104Apr 2, 1998Paper

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

Clinical Therapeutics
A DaviesI Schweitzer

Abstract

Haloperidol is widely considered a reference standard in antipsychotic therapy and is commonly used in comparative studies of the efficacy and safety of antipsychotic medication. Comparative clinical trials have shown that the novel antipsychotic agent risperidone tends to have greater efficacy (i.e., clinical response defined as a > or = 20% reduction in total scores on the Positive and Negative Syndrome Scale) than haloperidol in patients with chronic schizophrenia and poses less risk of extrapyramidal symptoms (EPS). We used DerSimonian and Laird's random-effects model to analyze pooled patient data from available randomized, double-masked, comparative trials of risperidone and haloperidol in patients with schizophrenia treated for at least 4 weeks at recommended doses. The purpose of the analysis was to determine whether there are significant overall differences in the rates of patient clinical response, prescription of anticholinergic agents, and treatment dropout. Six of the nine trials revealed in a literature search met all criteria for inclusion in the meta-analysis. The meta-analysis showed that in patients with chronic schizophrenia, risperidone therapy is associated with significantly higher response rates, signific...Continue Reading

References

Nov 2, 1991·Lancet·S G Thompson, S J Pocock
Feb 1, 1991·Annals of Internal Medicine·S N Goodman
Aug 1, 1987·Annals of Internal Medicine·K A L'AbbéK O'Rourke
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Feb 1, 1995·Journal of Clinical Psychopharmacology·R L Borison
Sep 24, 1994·BMJ : British Medical Journal·H J Eysenck
Nov 1, 1995·International Clinical Psychopharmacology·J CarmanA Vangeneugden
Jan 1, 1995·Schizophrenia Bulletin·D Umbricht, J M Kane
Jan 1, 1996·European Archives of Psychiatry and Clinical Neuroscience·H J Möller
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer

❮ Previous
Next ❯

Citations

Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Dec 31, 2002·Schizophrenia Research·V MolinaM Desco
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
Apr 26, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·R Bullock, S Libretto
Sep 17, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, R Bahbouh
Jan 26, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A J LoonenJ M Sitsen
Apr 1, 2003·International Journal of Mental Health Nursing·Brenda HappellJaya Pinikahana
Dec 15, 2005·Journal of Palliative Medicine·Douglas J Weschules
Jan 22, 2005·The Australian and New Zealand Journal of Psychiatry·Anne MagnusTheo Vos
Apr 7, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stephan RuhrmannMichael Philipp
Jan 1, 2011·Schizophrenia Research and Treatment·Patrick D McGorryTim Lambert
Jul 14, 2000·Current Medical Research and Opinion·B Green
Jul 5, 2005·Expert Opinion on Investigational Drugs·N A Keks, C Culhane
Aug 26, 2004·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Eduardo Pondé de SenaIrismar Reis de Oliveira
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Lecompte, R F Cookson
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·L C KopalaJ S Hellewll
Aug 16, 2003·Journal of Clinical Psychopharmacology·Frank GianfrancescoHenry A Nasrallah
Jul 5, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·H-J Möller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.